Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

33.00
+0.26000.79%
Volume:572.03K
Turnover:18.86M
Market Cap:5.73B
PE:-15.28
High:33.27
Open:32.89
Low:32.62
Close:32.74
52wk High:43.73
52wk Low:11.60
Shares:173.52M
Float Shares:166.83M
Volume Ratio:0.77
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-109.74%
ROA:-43.84%
PB:12.25
PE(LYR):-12.94

Loading ...

Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application

TIPRANKS
·
Sep 15

Cogent Biosciences, - FDA States no Advisory Committee Planned and no Review Issues Identified

THOMSON REUTERS
·
Sep 15

Cogent Biosciences Announces FDA Acceptance of New Drug Application (Nda) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (Advsm)

THOMSON REUTERS
·
Sep 15

Cogent Biosciences, - FDA Accepts Nda for Bezuclastinib in Advsm with Pdufa Date June 29, 2027

THOMSON REUTERS
·
Sep 15

Cogent Biosciences - to Purchase Minimum Percentages of Bezuclastinib Products from Hovione - SEC Filing

THOMSON REUTERS
·
Sep 03

Cogent Biosciences - Agreement Effective for Five-Year Term with Automatic Two-Year Renewals - SEC Filing

THOMSON REUTERS
·
Sep 03

Cogent Biosciences - Enters Commercial Supply Agreement with Hovione on Sept 1, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 03

Cogent Biosciences Signs Hovione Supply Deal for Bezuclastinib Tablets

Reuters
·
Sep 03

Cogent Biosciences Director Arlene Morris Disposes of USD 1.69 Million in Common Shares

Reuters
·
Sep 01

Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?

Simply Wall St.
·
Aug 17

Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next

Simply Wall St.
·
Aug 16

Cogent Biosciences, Inc. : Leerink Partners Cuts Target Price to $60 from $72

THOMSON REUTERS
·
Aug 12

Wedbush Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

TIPRANKS
·
Aug 11

Cogent Biosciences, Inc. : Guggenheim Raises Target Price to $52 from $45

THOMSON REUTERS
·
Aug 11

U.S. Research Roundup-Accendra Health, Celestica, Sionna Therapeutics

Reuters
·
Aug 11

Cogent Biosciences Files for USD 400 Million At-the-Market Stock Offering

Reuters
·
Aug 11

Cogent Biosciences - May Offer up to $400 Mln in Common Stock Through Guggenheim Securities - SEC Filing

THOMSON REUTERS
·
Aug 11

Sana Biotechnology Q2 Adjusted Loss Narrows, Beats Estimates

Reuters
·
Aug 11

Bionano Genomics Q2 Revenue Rises on Increased Clinical Adoption

Reuters
·
Aug 11

Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise

Reuters
·
Aug 11